Selected article for: "sample size and study sample size"

Author: Yueping Li; Zhiwei Xie; Weiyin Lin; Weiping Cai; Chunyan Wen; Yujuan Guan; Xiaoneng Mo; Jian Wang; Yaping Wang; Ping Peng; Xudan Chen; Wenxin Hong; Guangming Xiao; Jinxin Liu; Lieguang Zhang; Fengyu Hu; Feng Li; Feng Li; Fuchun Zhang; Xilong Deng; Linghua Li
Title: An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)
  • Document date: 2020_3_23
  • ID: 9hknw4ws_46
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.19.20038984 doi: medRxiv preprint 1 2 1 in Shanghai observed 134 patients with COVID-19 and did not find any effects of LPV/r and arbidol on relieving symptoms or accelerating virus clearance after treatment for 5 days [20] . Despite the small sample size, our study also suggests that monotherapy of LPV/r or arbidol might not improve the .....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.19.20038984 doi: medRxiv preprint 1 2 1 in Shanghai observed 134 patients with COVID-19 and did not find any effects of LPV/r and arbidol on relieving symptoms or accelerating virus clearance after treatment for 5 days [20] . Despite the small sample size, our study also suggests that monotherapy of LPV/r or arbidol might not improve the clinical outcome in treating with mild/moderate COVID-19.

    Search related documents:
    Co phrase search for related documents